Diagnosis and Management of Patent Ductus Arteriosus
- PMID: 30505242
- PMCID: PMC6269146
- DOI: 10.1542/neo.19-7-e394
Diagnosis and Management of Patent Ductus Arteriosus
Abstract
Preterm infants are at increased risk for patent ductus arteriosus (PDA). Prolonged exposure to PDA may be deleterious and has been associated with neonatal morbidity and mortality. Although the molecular mechanisms underlying regulation of postnatal ductus arteriosus closure are not fully understood, clinical experience and research trials have informed recent changes in PDA management strategies and refocused treatment strategies on smaller subsets of infants who require intervention. This review examines current diagnostic and management approaches to PDA in preterm neonates.
Figures

References
-
- El-Khuffash A, Weisz DE, McNamara PJ. Reflections of the changes in patent ductus arteriosus management during the last 10 years. Arch Dis Child Fetal Neonatal Ed. 2016;101(5):F474–F478 - PubMed
-
- Benitz WE. Treatment of persistent patent ductus arteriosus in preterm infants: time to accept the null hypothesis? J Perinatol. 2010;30(4):241–252 - PubMed
-
- Nemerofsky SL, Parravicini E, Bateman D, Kleinman C, Polin RA, Lorenz JM. The ductus arteriosus rarely requires treatment in infants >1000 grams. Am J Perinatol. 2008;25(10):661–666 - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources